Sales: $220 million (estimated) for household and personal care products. Corporate sales: $602 million for the year ended March 31, 2014.
Key Personnel: Matthew M. Mannelly, president and CEO; Ron Lombardi, chief financial officer; Timothy J. Connors, executive vice president, sales and marketing; Samuel C. Cowley; general counsel and vice president, business development; John Parkinson, senior vice president, international; Jean Boyko, senior vice president, science and technology; Paul Hennessey, vice president, operations; Paul T. Migaki, vice president, strategic planning, Canada and household products.
Major Products: Personal care, skin care, oral and OTC health care products including Chap-et Lip Balm, Cloverine, Debrox earwax remover, Dermoplast, Efferdent Denture Cleanser, Effergrip Denture Adhesive, Ezo denture, Gly-Oxide Oral Rinse, Kerodex, Kwellada-P Lice Treatment, Remedies, New-Skin Liquid Bandage, New-Skin Scar Fade, Outgro, Oxipor Psoriasis Lotion, The Doctor’s Night Guard. Household care products include Comet, Cinch and Spic and Span cleaners and Chore Boy scrubbing pads. The company also sells a number of GI-related medications and pain relievers for oral ingestion.
New Products: Efferdent Fresh Guard.
Comments: Prestige Brands’ net revenues for the fiscal year ended March 31, 2014 were $601.9 million, a decrease of 3.5% over the prior fiscal year. OTC segment revenues were $513.8 million, a decrease of 4.3%, which the firm said was driven by lower cough/cold incidence levels, the impact of the return of competitive products to the marketplace, and changes in retailer inventory levels. Fiscal 2014 revenues for the household cleaning segment, which represents less than 15% of overall company revenues, rose 1.5% to $88.0 million.
In April, Prestige Brands Holdings, Inc. entered into a definitive agreement to acquire Insight Pharmaceuticals Corporation, marketer and distributor of feminine care and other OTC healthcare products, for $750 million in cash. The deal adds Monistat OTC yeast infection treatment and EPT home pregnancy test products and other feminine care brands to Prestige’s portfolio. In addition to giving the company a platform in feminine care in the US and Canada, the Insight acquisition adds other personal care products from Caldesene and Gentle Naturals baby care products to first aid offerings like Nix lice treatment, Caldecort anti-itch cream and Skin Shield liquid bandage to cold and flu products to pain relievers.
Earlier in April, Prestige also acquired Hydralyte, a leading OTC oral rehydration brand sold in Australia and New Zealand.
According to Matthew M. Mannelly, CEO, Monistat will become the company’s first $100 million brand.
“The acquisition is expected to boost Prestige’s annual revenues to approximately $800 million, bringing us closer to our stated goal of becoming a billion dollar OTC products company,” Mannelly said in a statement when the Insight deal was announced.